Immunovant
Track in portfolio
Price chart
Description
Company and Business Model
Immunovant is a biotechnology company focused on developing innovative therapies for autoimmune diseases. Its core product is IMVT-1401, a monoclonal antibody designed to treat conditions such as myasthenia gravis. The company primarily operates in the healthcare sector, with its main revenue source being potential future sales of its therapeutic products. Immunovant is currently in the clinical development stage, with no commercialized products generating revenue.
Investment Profile
The investment profile of Immunovant is more aligned with growth investors due to its focus on developing new therapies and the potential for significant future revenue, albeit with high associated risks. The stock may not appeal to dividend or value investors given the lack of current profitability and established revenue streams.
Fundamental metrics (experimental) Updated: 2026-07-27
- EPS (TTM) — earnings per share for the last 12 months, $
- -2.78
- EPS surprise
- -23.3%
- 20d volatility
- 1.8%
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-07-13 | Hold | Sell | Weak fundamentals and high risk limit upside potential. |
| 2026-06-13 | Sell | Hold | Positive momentum, but fundamentals show significant weakness. |
| 2026-06-03 | Hold | Sell | Weak fundamentals and negative momentum raise significant concerns. |
| 2026-05-22 | Sell | Hold | Strong recent performance, but fundamentals remain weak. |
| 2026-05-16 | Hold | Sell | Weak fundamentals and negative momentum raise significant risk. |
| 2026-05-08 | — | Hold | Weak fundamentals and high risk; uncertain momentum. |
| 2026-05-08 | Hold | Hold | Компания Immunovant демонстрирует умеренный рост за последние месяцы, однако отрицательный EPS и высокая волатильность указывают на значительные риски. Рекомендуется удерживать акции до получения более ясных сигналов о ф |
| 2026-03-01 | — | Hold | Компания показывает значительный рост за последние месяцы, что указывает на позитивные ожидания инвесторов. Однако отрицательный EPS и отсутствие дивидендов могут свидетельствовать о рисках, связанных с финансами. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-05-21 | H.C. Wainwright | Target Raised | — → 40 | 35.56 |
| 2026-01-06 | Wolfe Research | Rating Upgraded | — → 50 | 24.97 |
| 2025-12-18 | Guggenheim | Target Lowered | 44 → 41 | 26.2689 |
| 2025-10-14 | Truist Financial | Update | — → 16 | 17.35 |
News Page 1 of 1
Nothing yet